undamentalytics Newsletter
Sign in

Starling Oncology, Inc. key statistics and ratios

In fiscal 2025, Starling Oncology, Inc. had a net margin of -12.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−7.6%−5.4%0.1%−25.6%−16.4%−12.1%−6.2%
Return on equity−51.0%−16.5%0.1%−92.2%———
Return on assets−21.8%−8.1%0.1%−35.3%−33.9%−35.9%−21.2%
SG&A as % of revenue22.3%41.1%47.4%35.1%27.4%21.0%19.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $178m
Short-term assets $129mLonger-term assets $49m
What it owes, and who funded it · $203m
Short-term liabilities $95mLonger-term liabilities $108mShareholders' equity $-25m
  • Short-term assets cover short-term liabilities $129m of assets due within a year against $95m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $129m short-term assets against $108m of longer-dated liabilities.
  • More cash than debt $41m of cash against $80m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $328,000 of operating cash flow against $80m of debt.
  • Operating profit covers interest at least five times over Operating income of −$26m against $8m of interest.

From Starling Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

12 /100

Weak moat

How hard Starling Oncology's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -23.4% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -17.6%; its worst year was -36.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -13.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CDNA vs STLNSTLN vs USPHCRVL vs STLN

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Starling Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Starling Oncology, Inc.